CINCINNATI, June 25, 2020 /PRNewswire/ — Dolbey is a leading provider of cloud- and premise-based speech recognition solutions for healthcare, with two premier speech recognition products – Fusion Narrate® powered by nVoq™ and Fusion SpeechEMR® powered by SpeechMagic™. In the Speech Recognition: Front-End EMR Segment Highlight report, Fusion Narrate received the highest overall score.
KLAS Research is a healthcare information technology data and insights company providing the industry with accurate, honest and impartial research on the software and services used by providers and payers worldwide. KLAS collects thousands of evaluations from healthcare providers to rate vendors across several categories. In June, KLAS released its detailed Speech Recognition: Front-End EMR Segment Highlight. The report compares front-end EMR speech recognition options from Dolbey, Nuance and 3M (MModal) complete with scores and ratings in categories such as product, value, relationship and operations.
“Delivering quality products to the healthcare market with higher customer satisfaction has always been the goal at Dolbey and Company,” said Bob Leslie, Dolbey and Company Senior Vice President and General Manager. “We are very pleased to receive straight-A ratings from our customers for both of our speech recognition applications. Along with excellent speech recognition, our Fusion Narrate cloud application has brought new navigational tools that allow physicians and other healthcare providers to quickly maneuver in their EHR, thereby reducing clicks and significantly decreasing documentation time.”
Dolbey’s cloud-based solution, Fusion Narrate, has been tested for compatibility with nearly 100 EHRs and can natively interoperate with most healthcare applications, with no integration required. Fusion SpeechEMR, Dolbey’s premise-based front-end speech recognition solution, is designed to integrate with all major LIS and Digital Pathology systems without the need for interfaces. Both Fusion Narrate and Fusion SpeechEMR can be used to reduce transcription costs and minimize clicks and keystrokes, freeing up providers to focus more on the patient and less on documentation.
Visit the KLAS Speech Recognition – Front-End EMR market segment for a comparison and full breakdown of available front-end EMR speech recognition options.
About Dolbey
Dolbey’s award-winning healthcare suite of solutions improve productivity while delivering better documentation, improving patient care. Since 1914, Dolbey has consistently evolved its products, incorporating the latest technologies available to meet the demands of the healthcare community. Today, Dolbey’s suite of products includes speech recognition (premise- or cloud-based), CAPD, CDI, CAC, transcription and dictation. To learn more about Dolbey’s front-end speech recognition software for EMRs, visit www.fusionnarrate.com.
About KLAS
KLAS is a data-driven company on a mission to improve the world’s healthcare by enabling provider and payer voices to be heard and counted. Working with thousands of healthcare professionals, KLAS collects insights on software, services and medical equipment to deliver reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly reflects the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights it provides, visit www.klasresearch.com
For further information, please contact Brian Gaysunas, Marketing Specialist, at 800-756-7828 ext. 210 or at bgaysunas@dolbeyco.com.
Related Images
dolbey-logo.jpg
Dolbey Logo
Dolbey Logo
View original content to download multimedia:http://www.prnewswire.com/news-releases/dolbey-fusion-narrate-receives-the-highest-user-score-for-front-end-speech-recognition-for-emrs-in-new-klas-2020-report-301083389.html
SOURCE Dolbey
NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to…
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…